The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.
 
Junichi Matsubara
No Relationships to Disclose
 
Kumi Mukai
No Relationships to Disclose
 
Masahiro Yoshioka
No Relationships to Disclose
 
Hidenori Kage
Research Funding - Konica Minolta (Inst)
 
Katsutoshi Oda
Honoraria - AstraZeneca/Merck; Chugai Pharma; Takeda
Research Funding - AstraZeneca/Merck; Konica Minolta
 
Ryo Kudo
No Relationships to Disclose
 
Sadakatsu Ikeda
Honoraria - ACT Genomics; ACT Med; AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical; Canon Medical System; Chugai Pharma; Guardant Health; MSD; Novartis; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Genodive pharma (Inst)
Research Funding - ACT Genomics (Inst); Canon Medical System (Inst); Hitachi (Inst)
 
Hiromichi Ebi
Honoraria - Amgen; Bristol-Myers Squibb Japan; Incyte Japan; Merck Serono
Consulting or Advisory Role - Amgen; Merck Serono
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Solasia Pharma
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Ryuji Hayashi
No Relationships to Disclose
 
Nahomi Tokudome
Honoraria - Boehringer Ingelheim; Chugai Pharma
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - A2 Healthcare; Abbvie (Inst); Amgen; Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation; IQvia; Janssen (Inst); Lilly (Inst); Mebix; MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Manabu Muto
Speakers' Bureau - Canon Medical System; Chugai Pharma; Daiichi Sankyo/Lilly; Illumina; Incyte Japan; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Shionogi
Research Funding - Canon Medical System; Chugai Pharma; H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical